0 153

Cited 0 times in

Effects of intravenous iron therapy on mortality and hospitalization of hemodialysis patients: A prospective cohort study in Korea

Authors
 Hyunjin Ryu  ;  Jung Pyo Lee  ;  Sohee Oh  ;  Jang-Hee Cho  ;  Byung Ha Chung  ;  Sungjin Chung  ;  Jae Hyun Chang  ;  Jin Ho Hwang  ;  Shin-Wook Kang  ;  Chun Soo Lim 
Citation
 CLINICAL NEPHROLOGY, Vol.97(2) : 78-85, 2022-02 
Journal Title
CLINICAL NEPHROLOGY
ISSN
 0301-0430 
Issue Date
2022-02
MeSH
Hospitalization ; Humans ; Iron ; Kidney Failure, Chronic* / complications ; Kidney Failure, Chronic* / diagnosis ; Kidney Failure, Chronic* / therapy ; Longitudinal Studies ; Prospective Studies ; Renal Dialysis*
Abstract
Iron replacement therapy is necessary for anemia treatment in patients with advanced chronic kidney disease. Intravenous (IV) iron therapy is an efficient method for iron replacement. However, there are concerns regarding its considerable side effects, including increased risks of infection or major adverse cardiovascular events (MACE). This is a longitudinal study from a multicenter prospective cohort study conducted in the Korean end-stage renal disease population. All-cause mortality, death due to infection or MACE, hospitalization due to infection or MACE, and all adverse event of death or hospitalization due to infection or MACE were compared according to the iron replacement methods during the first 3 months of enrollment. Among 1,680 hemodialysis patients, 29.3% of patients received IV iron therapy, and 38% of patients received oral iron therapy. During the median 632 days follow-up, all-cause mortality, mortality or hospitalization due to infection or MACE, and all adverse events did not differ among iron replacement groups. There were significant differences related to the risk of all adverse events among iron replacement therapies in the log-rank test and univariate Cox regression analysis only in the prevalent dialysis patients; however, the significance was lost in multivariate Cox regression analysis. Similar results were observed in the 1-year short-term outcome analysis. High-dose IV iron did not increase adverse outcomes. All-cause mortality or all adverse events due to infection or MACE were not higher with the current clinical regimen of IV iron replacement therapy than with oral or no iron therapy in Korean hemodialysis patients.
Full Text
https://www.dustri.com/article_response_page.html?artId=188614&doi=10.5414/CN110042&L=0
DOI
10.5414/CN110042
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kang, Shin Wook(강신욱) ORCID logo https://orcid.org/0000-0002-5677-4756
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/193490
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links